Fast track PMR clinics in Denmark led to more patients seen, and time to referral went down. If we don’t get in early with a right diagnosis (and maybe early steroid-sparing) then PMR patients deteriorate. We shouldn’t let PMR be an end stage disease #EULAR2025 POS0136 @RheumNow https://t.co/pqwveamhJP

• https://x.com/drdavidliew/status/1933074135015698861/photo/1

In SLEek LTE, ABBV-599 HD (BTKi+JAKi) & UPA 30mg sustained or improved disease control through 104wks: SRI-4 ≥82%, ↓flares, near steroid-free, no new safety signals. PBO-switchers improved too. Targeted oral combos look promising. @RheumNow #EULAR2025 #OP0198 https://t.co/IHXC2iD0h6

• https://x.com/DrMiniDey/status/1933081588700439034/photo/1

Data from Dutch registry SpA-Net explored prevalence using new definitions for D2M axSpA. -Smoking and psoriasis were characteristics associated with D2M disease. -In the three variations explored, the lowest prevalence was observed in the variation based purely on objective https://t.co/h3f4ORQl0F

• https://x.com/AdelaCastro222/status/1933069705465524705/photo/1
• https://x.com/AdelaCastro222/status/1933069705465524705/photo/1

Sex differences in biologic response in PsA. DISCOVER-2 post hoc analysis showed: •Radiographic progression at Week ♂️: 2.22 units ♀️: 1.10 units •Early ACR-like response (cDAPSA LDA at 8wks) linked to less damage in men (0.39 vs 2.24) Women less likely to progress https://t.co/NhBkXbuLjO

• https://x.com/synovialjoints/status/1932823344195182987/photo/1

#EULAR2025 Abstr#OP0006. There is no standardised definition for complete renal response in #lupus nephritis. Post-hoc analysis of REGENCY showed Obinutuzumab + SOC was superior to PBO + SOC if endpoints for voclosporin and belimumab RCTs were used. Effect size ~13-16% @RheumNow https://t.co/q8MNAV8XF3

• https://x.com/Yuz6Yusof/status/1932929355761520692/photo/1

Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/pG3aN3o4GZ

T2T in #gout w serum #uric #acid / #urate target SAVES LIVES Study of achievement of target 🎯 ⬇️CVE and death If not achieving Urate <360 T2T also reduced baseline #SUA #EULAR2025 @rheumnow abst#OP0005 https://t.co/ePchJ4vqnU

• https://x.com/Janetbirdope/status/1932879622661693936/photo/1

#Oninutuzumab works in #lupus #nephritis #LN no matter how you vary the #renal #responses Of various definitions of #Complete & #Partial #renal #responses abst#OP0006 #EULAR25 @eular_org @RheumNow Not surprised 😲 https://t.co/Zn2lXkddez

• https://x.com/Janetbirdope/status/1932879643616456951/photo/1
• https://x.com/Janetbirdope/status/1932879643616456951/photo/1

1 shot will do! #symptomatic #Knee #OA given #gene #therapy #intra-#articular Seemed to last up to 104 weeks! But no placebo small safety study but sustained #WOMAC responses Needs large #RCT but v interesting #EULAR2025 @RheumNow @eular_org Abst# POS0492 https://t.co/hqTqBorrbA

• https://x.com/Janetbirdope/status/1932879669746876601/photo/1
• https://x.com/Janetbirdope/status/1932879669746876601/photo/1

Exciting results from ARGO trial: -Phase 2 of Sonelokimab (dual IL-17A-IL17F) nanobody in PsA. -Met primary endpoint of ACR50 at week 12 vs PBO. -62% achieved MDA -48% achieved composite of ACR 70+PASI 100 Looking forward to phase 3 results!!! Abstract #OP0096 #EULAR2025 https://t.co/1D52eG8ReS

• https://x.com/AdelaCastro222/status/1932899283579383966/photo/1
• https://x.com/AdelaCastro222/status/1932899283579383966/photo/1
• https://x.com/AdelaCastro222/status/1932899283579383966/photo/1

Insights from the Gut-Joint Axis in axSpA: Findings from the DESIR cohort -Baseline biomarkers of bacterial translocation: PLTP (phospholipid transfer protein) and LPS evaluated. -In early axSpA baseline PLTP activity was associated with sacroiliac radiographic progression at 5

So much needed in SLE and pregnancy 1. Risk stratification at diagnosis 2. Pregnancy counseling at dx and >1 y before pregnancy 3. Close collab with GYN necessary 4. Challenging management given gaps in evidence. #EULAR2025 #asktheexpert @RheumNow https://t.co/MXGkKpl452

• https://x.com/AdelaCastro222/status/1932909268208124100/photo/1
• https://x.com/AdelaCastro222/status/1932909268208124100/photo/1

Secukinumab for PMR? -post hoc analysis of the TitAIN study (phase 2 RCT on new onset/relapsing GCA) showed: -Numerical reduction in patients experiencing PMR symptoms when treated with secukinumab compared to placebo. -Safety profile was similar to the overall GCA study

Biomarker data suggest TNFi non-responders in PsA exhibit upregulation of IL-17F gene signatures after treatment failure. Supports IL-17A/F blockade rationale with bimekizumab in TNFi-experienced patients Abstract#OP0091 @RheumNow . #EULAR2025 https://t.co/CWR6ArDRRW

• https://x.com/synovialjoints/status/1932912825858429121/photo/1

Real-world study on dual bDMARD plus JAKi or TYK2i combinations in refractory PsA. 22 PsA patients on dual bDMARD + JAKi/TYK2i: •Most common: IL-17i + TYK2i •Total exposure: 8.5–10.5 pt-years •Only mild URIs/stomatitis •Clinical improvements seen in joint/skin domains https://t.co/waDReDqSDE

• https://x.com/synovialjoints/status/1932914389482401852/photo/1